BKBart-Jan Kroesen

Bart-Jan Kroesen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bart-Jan Kroesen has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessing Serum Neurofilament Light Chain in Hereditary Transthyretin Amyloidosis: Direct Comparison of Three Immunoassays

    by Milou Berends, Johan Bijzet, Suzanne Arends, Elisabeth Brouwer, Charlotte E. Teunissen, Sjors G. J. G. In ’T Veld, Reinold O. B. Gans, Bouke P. C. Hazenberg, Paul A. van der Zwaag, Hans L. A. Nienhuis, et al.

    Background/Objectives: Serum neurofilament light chain (sNfL) is an early and sensitive biomarker of polyneuropathy. This study compared the UmanDiagnostics enzyme-linked immunosorbent assay (ELISA), and Meso Scale Discovery (MSD) R-PLEX assay with the current gold-standard single-molecule array (Simoa) assay for sNfL measurement. Methods: sNfL levels were measured with Simoa, ELISA, and MSD R-PLEX in 330 serum samples from 73 individuals with a pathogenic transthyretin gene variant (TTRv) and in 165 healthy controls (HC) with ELISA and MSD R-PLEX. Results: Median sNfL levels, assessed in serum samples from TTRv individuals, differed across all assays (all p < 0.001). Passing–Bablok regression slopes were 1.01 (Simoa–ELISA), 1.00 (Simoa–MSD R-PLEX), and 1.02 (MSD R-PLEX-ELISA), with very strong correlations (all r > 0.8). Bland–Altman analysis showed mean differences of 0.1 ± 0.2 pg/mL (Simoa–ELISA), 0.7 ± 0.1 pg/mL (Simoa–MSD R-PLEX), and −0.6 ± 0.2 pg/mL (MSD R-PLEX-ELISA). In HC, sNfL levels positively correlated with age. Z-score normalization allowed for inter-assay comparison. Conclusions: The ELISA and MSD R-PLEX assays provide suitable alternatives for the Simoa assay to measure sNfL levels in carriers of a pathogenic TTR-gene variant. The differences in concentrations defined by the assays directly relate to the internal standard provided with the assays.

  • Open Access

    Baseline Blood CD8+ T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer

    by Hanneke Kievit, M. Benthe Muntinghe-Wagenaar, Wayel H. Abdulahad, Abraham Rutgers, Lucie B. M. Hijmering-Kappelle, Birgitta I. Hiddinga, J. Fred Ubbels, Robin Wijsman, Marcel J. van der Leij, Johan Bijzet, et al.

    Background: Tumor-infiltrating immune cells have been correlated with prognosis for patients treated with immune checkpoint inhibitor (ICI) treatment of various cancers. However, no robust biomarker has been described to predict treatment response yet. We hypothesized that the activation potency of circulating T cells may predict response to ICI treatment. Methods: An exploratory analysis was conducted to investigate the association between the response to immune checkpoint inhibition (ICI) combined with stereotactic radiotherapy (SBRT) and the potency of circulating T cells to be activated. Blood-derived lymphocytes from 14 patients were stimulated ex vivo with, among others, Staphylococcal enterotoxin B (SEB) and compared to healthy controls (HCs). Patients were grouped into responders (>median progression free survival (PFS)) and non-responders (+ and CD8+ T cells in response to stimulation was measured using flow cytometry. In addition, serum levels of BAFF, IFNγ, and IL-2 receptor (sIL-2R) were measured by Luminex. Results: At baseline, a higher percentage of activated CD8+ T cells (15.8% vs. 3.5% (p = +CD69+CD8+ T cells (8.8% vs. 2.9% (p = 0.02)) was observed in responders compared to non-responders upon ex vivo stimulation with SEB. The concurrently measured serum cytokine levels were not different between responders and non-responders. Conclusion: Baseline blood CD8+ T cell activation potency, measured by intracellular cytokine production after ex vivo stimulation, is a potential biomarker to discriminate responders from non-responders to SBRT combined with ICI.


  • Open Access

    High-Sensitivity Cardiac Troponin T to Exclude Cardiac Involvement in TTR Variant Carriers and ATTRv Amyloidosis Patients

    by Hendrea S. A. Tingen, Milou Berends, Alwin Tubben, Johan Bijzet, Ewout J. Houwerzijl, Friso L. H. Muntinghe, Bart-Jan Kroesen, Paul A. van der Zwaag, Peter van der Meer, Riemer H. J. A. Slart, et al.

    (1) Background: Individuals carrying a pathogenic transthyretin gene variant (TTRv) are at high risk for developing hereditary transthyretin (ATTRv) amyloidosis and are routinely screened for the development of cardiomyopathy (ATTRv-CM). This study aims to evaluate whether the cardiac biomarkers N-terminal pro B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) can be used to rule out ATTRv-CM. (2) Methods: In this retrospective case-control study, data from 46 ATTRv-CM patients and 101 TTRv carriers and ATTRv amyloidosis patients without cardiomyopathy were included. Binary logistic regression models were used to assess the ability of NT-proBNP and hs-cTnT to predict the diagnosis of ATTRv-CM. An optimal cutoff for the relevant biomarker(s) was determined based on a sensitivity of ≥99% and the highest possible percentage of additional tests avoided (%ATA) in the index dataset. (3) Results: Hs-cTnT demonstrated the highest predictive capabilities for ATTRv-CM. The addition of NT-proBNP did not improve the predictive model. A hs-cTnT cutoff of TTRv carriers and ATTRv amyloidosis patients and it has the potential to prevent unnecessary diagnostic procedures.


  • Open Access

    Involvement of MicroRNAs in the Aging-Related Decline of CD28 Expression by Human T Cells

    by Nato Teteloshvili, Gerjan Dekkema, Annemieke M. Boots, Peter Heeringa, Pytrick Jellema, Debora de Jong, Martijn Terpstra, Elisabeth Brouwer, Graham Pawelec, Klaas Kok, et al.

    Loss of CD28 is a characteristic feature of T cell aging, but the underlying mechanisms of this loss are elusive. As differential expression of microRNAs (miRNAs) has been described between CD28+ and CD28− T cells, we hypothesized that altered miRNA expression contributes to the age-associated downregulation of CD28. To avoid the confounding effects of age-associated changes in the proportions of T cells at various differentiation stages in vivo, an experimental model system was used to study changes over time in the expression of miRNA associated with the loss of CD28 expression in monoclonal T cell populations at a lower or higher number of population doublings (PDs). This approach allows identification of age-associated miRNA expression changes in a longitudinal model. Results were validated in ex vivo samples. The cumulative number of PDs but not the age of the donor of the T cell clone was correlated with decreased expression of CD28. Principal component analysis of 252 expressed miRNAs showed clustering based on low and high PDs, irrespective of the age of the clone donor. Increased expression of miR-9-5p and miR-34a-5p was seen in clones at higher PDs, and miR-9-5p expression inversely correlated with CD28 expression in ex vivo sorted T-cells from healthy subjects. We then examined the involvement of miR-9-5p, miR-34a-5p, and the members of the miR-23a~24-2 cluster, in which all are predicted to bind to the 3′UTR of CD28, in the IL-15-induced loss of CD28 in T cells. Culture of fresh naive CD28+ T cells in the presence of IL-15 resulted in a gradual loss of CD28 expression, while the expression of miR-9-5p, miR-34a-5p, and members of the miR-23a~24-2 cluster increased. Binding of miR-9-5p, miR-34a-5p, miR-24-3p, and miR-27- 3p to the 3′UTR of CD28 was studied using luciferase reporter constructs. Functional binding to the 3′UTR was shown for miR-24-3p and miR-27a-3p. Our results indicate involvement of defined miRNAs in T cells in relation to specific characteristics of T cell aging, i.e., PD and CD28 expression.


  • Hitting the brake: miR-31 regulates CD8 T cell effector function

    by Nato Teteloshvili, Joost Kluiver, Anke van Den Berg, Bart-Jan Kroesen

    Cytotoxic CD8 T cells have pivotal effector and regulatory immune-functions and are, as such, involved in the host-immune response following infection. Dysfunction of CD8 T cells, on the other hand, may contribute to autoimmunity. CD8 T cells exert their function by releasing cytotoxic mediators and cytokines. Acute infection triggers a response to effectively clear the pathogen and develop long-lasting protective memory, while chronic infections may lead to exhaustion and dysfunction of CD8 T cells. The latter phenomenon relates to the tunable balance of the immune system to preserve tolerance and prevent development of autoimmunity. CD8 T cells also play a crucial role in preventing development of cancer cells. Tumor cells may evade an effective anti-tumor immune response and clinical exploitation of immune checkpoints to break this tolerance and induce anti-tumor immunity clearly illustrates the two-edged characteristics of the immune response. Vice versa, autoimmune disorders and chronic infections may lead to the onset of cancer, which suggests that these pathological conditions may share mutual pathways. Understanding the molecular basis of autoreactive and defective CD8 T cell responses provides a basis for the rational design of immunotherapies aiming to restore CD8 T cell function and combat chronic viral infections and cancer.

  • Immuno‐miRs: critical regulators of T‐cell development, function and ageing

    by Bart‐Jan Kroesen, Nato Teteloshvili, Katarzyna Smigielska‐Czepiel, Elisabeth Brouwer, Anne Mieke H. Boots, Anke van Den Berg, Joost Kluiver

    Summary: MicroRNAs (miRNAs) are instrumental to many aspects of immunity, including various levels of T‐cell immunity. Over the last decade, crucial immune functions were shown to be regulated by specific miRNAs. These ‘immuno‐miRs’ regulate generic cell biological processes in T cells, such as proliferation and apoptosis, as well as a number of T‐cell‐specific features that are fundamental to the development, differentiation and function of T cells. In this review, we give an overview of the current literature with respect to the role of miRNAs at various stages of T‐cell development, maturation, differentiation, activation and ageing. Little is known about the involvement of miRNAs in thymic T‐cell development, although miR‐181a and miR‐150 have been implicated herein. In contrast, several broadly expressed miRNAs including miR‐21, miR‐155 and miR‐17~92, have now been shown to regulate T‐cell activation. Other miRNAs, including miR‐146a, show a more T‐cell‐subset‐specific expression pattern and are involved in the regulation of processes unique to that specific T‐cell subset. Importantly, differences in the miRNA target gene repertoires of different T‐cell subsets allow similar miRNAs to control different T‐cell‐subset‐specific functions. Interestingly, several of the here described immuno‐miRs have also been implicated in T‐cell ageing and there are clear indications for causal involvement of miRNAs in immunosenescence. It is concluded that immuno‐miRs have a dynamic regulatory role in many aspects of T‐cell differentiation, activation, function and ageing. An important notion when studying miRNAs in relation to T‐cell biology is that specific immuno‐miRs may have quite unrelated functions in closely related T‐cell subsets.


  • Open Access

    Comprehensive analysis of miRNA expression in T-cell subsets of rheumatoid arthritis patients reveals defined signatures of naive and memory Tregs

    by K Smigielska-Czepiel, A van Den Berg, P Jellema, R J van der Lei, J Bijzet, J Kluiver, A M H Boots, E Brouwer, B-J Kroesen

    Disturbed expression of microRNAs (miRNAs) in regulatory T cells (Tregs) leads to development of autoimmunity in experimental mouse models. However, the miRNA expression signature characterizing Tregs of autoimmune diseases, such as rheumatoid arthritis (RA) has not been determined yet. In this study, we have used a microarray approach to comprehensively analyze miRNA expression signatures of both naive Tregs (CD4+CD45RO-CD25++) and memory Tregs (CD4+CD45RO+CD25+++), as well as conventional naive (CD4+CD45RO−CD25−) and memory (CD4+CD45RO+CD25−) T cells (Tconvs) derived from peripheral blood of RA patients and matched healthy controls. Differential expression of selected miRNAs was validated by TaqMan-based quantitative reverse transcription-PCR. We found a positive correlation between increased expression of miR-451 in T cells of RA patients and disease activity score (DAS28), erythrocyte sedimentation rate levels and serum levels of interleukin-6. Moreover, we found characteristic, disease- and treatment-independent, global miRNA expression signatures defining naive Tregs, memory Tregs, naive Tconvs and memory Tconvs. The analysis allowed us to define miRNAs characteristic for a general naive phenotype (for example, miR-92a) and a general memory phenotype (for example, miR-21, miR-155). Importantly, the analysis allowed us to define miRNAs that are specifically expressed in both naive and memory Tregs, defining as such miRNA signature characterizing the Treg phenotype (that is, miR-146a, miR-3162, miR-1202, miR-1246 and miR-4281).


  • Open Access

    Dual Role of miR-21 in CD4+ T-Cells: Activation-Induced miR-21 Supports Survival of Memory T-Cells and Regulates CCR7 Expression in Naive T-Cells

    by Katarzyna Smigielska-Czepiel, Anke van Den Berg, Pytrick Jellema, Izabella Slezak-Prochazka, Henny Maat, Hilda van Den Bos, Roelof Jan van der Lei, Joost Kluiver, Elisabeth Brouwer, Anne Mieke H. Boots, et al.

    Immune cell-type specific miRNA expression patterns have been described but the detailed role of single miRNAs in the function of T-cells remains largely unknown. We investigated the role of miR-21 in the function of primary human CD4+ T-cells. MiR-21 is substantially expressed in T-cells with a memory phenotype, and is robustly upregulated upon αCD3/CD28 activation of both naive and memory T-cells. By inhibiting the endogenous miR-21 function in activated naive and memory T-cells, we showed that miR-21 regulates fundamentally different aspects of T-cell biology, depending on the differentiation status of the T-cell. Stable inhibition of miR-21 function in activated memory T-cells led to growth disadvantage and apoptosis, indicating that the survival of memory T-cells depends on miR-21 function. In contrast, stable inhibition of miR-21 function in activated naive T-cells did not result in growth disadvantage, but led to a significant induction of CCR7 protein expression. Direct interaction between CCR7 and miR-21 was confirmed in a dual luciferase reporter assay. Our data provide evidence for a dual role of miR-21 in CD4+ T cells; Regulation of T-cell survival is confined to activated memory T-cells, while modulation of potential homing properties, through downregulation of CCR7 protein expression, is observed in activated naive T-cells.